Combinational BET and mTOR inhibition unveils EGR1 as acute myeloid leukemia prognostic biomarker
Rattachement africain : br. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
This study investigated the anti-leukemic potential of BET inhibitors in combination with mTOR inhibitors, focusing on both BET-resistant and BET-sensitive AML cell lines. Our findings reveal a significant suppression of proliferation and induction of apoptosis across all tested cell lines following combined treatment. Interestingly, JQ1 (a specific BET inhibitor) triggered cell cycle arrest only in sensitive cells when used alone while addition of mTOR inhibitors extended this antiproliferative effect to BET-resistant cells as well. This observation underscores the potential of this combination therapy to circumvent existing resistance mechanisms. This study further confirmed an additive antitumor effect of the combined inhibitors in primary AML patient cells. We also identified EGR1 as a predictive biomarker for treatment efficacy, which was correlated with increased levels of EGR1, a protein linked to enhanced overall survival. In silico analysis suggested better prognosis for AML patients with higher EGR1 expression. This study validates the combined use of BET and mTOR inhibitors as a promising treatment strategy for AML, capable of overcoming resistance and enhancing therapeutic outcomes. Furthermore, our investigation also highlights EGR1 not only as a biomarker of treatment response, but also as a potential target for future therapeutic interventions, offering valuable insights for patient management.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Combinational BET and mTOR inhibition unveils EGR1 as acute myeloid leukemia prognostic biomarker
- Date Crossref
- 18/11/2025
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Hospital Sírio-Libanês pays non établi dans la noticeÉtablissement de santé
-
Instituto do Câncer do Estado de São Paulo Divisão de Hematologia pays non établi dans la noticeÉtablissement de santé
-
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo Hospital das Clínicas da Faculdade de Medicina (HCFMUSP) pays non établi dans la noticeÉtablissement de santé
-
Universidade de São Paulo pays non établi dans la noticeUniversité ou école supérieure
-
Hospital Israelita Albert Einstein Faculdade Israelita de Ciências da Saúde Albert Einstein pays non établi dans la noticeOrganisme public
-
Universidade Federal de São Paulo Departamento de Oncologia Clínica e Experimental pays non établi dans la noticeUniversité ou école supérieure
Hospital Sírio-Libanês, Divisão de Hematologia — Instituto do Câncer do Estado de São Paulo et Hospital das Clínicas da Faculdade de Medicina (HCFMUSP) — Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.